Member Info for JimiHendrix

It’ll be a lot more than a million!

Slacker lol it was 500k last year and it’ll be a lot more this year as you well know.

900 people represent about 1% of the total market so I’d estimate the value is about £85,000 per year from this one. Lots more to come with total UK market worth £8.5m.

MT-RNR1 also has a total UK market of £8.5m. Scottish full adoption on its way first, hopefully by April as they are just waiting for the funding up there to be signed off.

Disappointing day but I put it down to being a Friday and the curse of ZM. It always seems to go down when he features GDR lol, maybe market makers use it as a signal to drop it. On brief glance there looks like there’s been some decent buying so can’t see why it’s dropped this much. Possibly just a retest of that bottom before heading up properly in anticipation of spirit results and the other positive news expected imminently.

Nobody was expecting a large contract until after the pilot study results have been published in April.

This is the first of possibly several hospitals taking up routine adoption/use before the pilot finishes. Exactly what the company said would happen. It’s a big relief to see things are on track :)

I’m not sure it’s the same hospital mentioned there Eureka, as the Peterborough City Hospital is managed by North West Anglia NHS Foundation Trust.

I think it’s one of the “several others” mentioned here from December’s presentation…

“First sales to largest Hyper Acute Stroke Centre in NHSE & several other stroke centres expected to implement in advance of NHSE pilot concluding”

In which case there could well be more to come imminently as the pilot concludes end of this month.

This is the first time that CYP2C-19 testing for stroke patients has been adopted for routine use in England, and it’s using POC testing rather than a lab.

Excellent news as anticipated from the presentation in December, things are going to plan. More to come I believe with the stroke pilot study finishing in 2 weeks.

Slacker, for the pilot study why do you think almost one third of testing (based on the number of people covered by the trusts taking part) is being done on the POC?

There are news items that are not always announced via RNS. We had an RNS for the tax credit last year, but not previous years.

The news I’ve referred to is from the presentation, most of it expected Q1.

I’m talking about the stroke test Guy, I believe we are very near. The implementation guide will be published next month.

*plus the tax credit

If the pilot is the model that gets rolled out to the national population then that’s approximately one third of the uk market. One third of £8.5m is approx £3m plus Scottish rollout of MT-RNR1, plus 9 NICUs already using it and 5 more to be announced soon. The income from that alone plus the tax pretty much covers the current cash burn.

Then consider the CFO’s statement “ pipeline of opportunities that, if converted, would see a significant step up in revenues during calendar year 2025 and a reduction in the level of cash burn.”

And then on top of the CE-IVD for selling in the EU is expected by April and I think it’s clear the company is well on the road to some really decent income. The share price will be multiples of where it is now!

Northern Care Alliance (for point-of-care testing) is a huge trust, approximately handling the same number of people as Royal Devon and Doncaster & Bassetlaw combined. I think that says a lot about the role POC testing is going to play in national rollout.

“The project will be led by the NHS Network of Excellence in Pharmacogenomics, in partnership with the National Stroke Programme and the NHS Genomics Unit. It will involve four NHS Foundation Trusts: Northern Care Alliance (for point-of-care testing), and Royal Devon, St George’s University Hospitals, and Doncaster and Bassetlaw (for laboratory-based testing).

The project is led by Dr Videha Sharma (Clinical Innovation Lead) and Emma Parnell (Design for Joy), and will follow an design-led approach, meaning it will gather feedback and make improvements as it progresses through the following phases:

* Design Phase (October – November 2024)

* Refinement and Pilot Setup (December 2024 – January 2025)

* Pilot Monitoring and Evaluation (February – March 2025)

This approach will provide a functioning service model that combines laboratory and point-of-care genetic testing at a small number of sites. This will be the first step towards a nationwide service, informed by front-line needs and requirements. These requirements will be shared through the implementation guide as well as inform commissioning decisions. These outputs are anticipated to be delivered in April 2025.”

Yeah it’ll push up really quick on a bit more buying volume. Plenty of news expected before the end of the month. Hopefully we’ll then have something similar to last year when the share price increased 250% in the few days from the results to the investor presentation in early April.

The publishing of the pilot study results could come anytime in April and a concrete plan to use POC for at least some of the CYP2C19 testing will do wonders for the share price from this level.

Lots more too including Scottish rollout, tax credit, further stroke test rollout, 5 further NICUs adopting RNR1 and CE-IVD approval! :)

Yes that’s my understanding too. Only a couple of weeks until the English pilot study concludes now, so much positive news expected in the next couple of weeks, it’s getting exciting. Going by last year we may have news this week to confirm receipt of a £700,000 tax credit and then my guess is CE-IVD marking will be next for selling in the EU.

Deramping again, it’ll say the same for almost every stock on the AIM market. It’s meaningless as these companies are driven by news and if things go as expected the revenues will very soon be vastly higher, genedrive has to be one of the best opportunities on AIM.

Stocksaint, it’s not rubbish …it came directly from a contact of mine who works on an NHS Scotland health board.

I see Lionel beat me to it! The jmdjournal was posted yesterday. Well worth reading for anybody who hasn’t read it or is having doubts about the POC approach. For this to be written just a few weeks before the pilot study finishes tells me we can expect some very good news.